124 related articles for article (PubMed ID: 3459594)
1. Clinical pharmacology of 4-demethoxydaunorubicin (DMDR).
Lu K; Savaraj N; Kavanagh J; Feun LG; Burgess M; Bodey GP; Loo TL
Cancer Chemother Pharmacol; 1986; 17(2):143-8. PubMed ID: 3459594
[TBL] [Abstract][Full Text] [Related]
2. Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study.
Pannuti F; Camaggi CM; Strocchi E; Comparsi R; Angelelli B; Pacciarini MA
Cancer Chemother Pharmacol; 1986; 16(3):295-9. PubMed ID: 3457647
[TBL] [Abstract][Full Text] [Related]
3. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.
Ganzina F; Pacciarini MA; Di Pietro N
Invest New Drugs; 1986; 4(1):85-105. PubMed ID: 3516918
[TBL] [Abstract][Full Text] [Related]
4. Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma.
Scher HI; Yagoda A; Ahmed T; Budman D; Sordillo P; Watson RC
Cancer Chemother Pharmacol; 1985; 14(1):79-80. PubMed ID: 3855289
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer.
Kris MG; Gralla RJ; Kelsen DP; Casper ES; Burke MT; Fiore JJ; Cibas IR; Heelan RT
Am J Clin Oncol; 1985 Oct; 8(5):377-9. PubMed ID: 3864366
[TBL] [Abstract][Full Text] [Related]
6. Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer.
Berman E; Wittes RE; Leyland-Jones B; Casper ES; Gralla RJ; Howard J; Williams L; Baratz R; Young CW
Cancer Res; 1983 Dec; 43(12 Pt 1):6096-101. PubMed ID: 6580068
[TBL] [Abstract][Full Text] [Related]
7. Intravenous and oral demethoxydaunorubicin (NSC 256-439) in the treatment of acute leukemia and lymphoma: a pilot study.
Eridani S; Slater NG; Singh AK; Pearson TC
Blut; 1985 Jun; 50(6):369-72. PubMed ID: 3859341
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.
Gillies HC; Herriott D; Liang R; Ohashi K; Rogers HJ; Harper PG
Br J Clin Pharmacol; 1987 Mar; 23(3):303-10. PubMed ID: 3471265
[TBL] [Abstract][Full Text] [Related]
9. The new anthracycline 4-demethoxydaunorubicin by oral route in advanced pretreated breast cancer and melanoma. A pilot study.
Martoni A; Pacciarini MA; Pannuti F
Drugs Exp Clin Res; 1985; 11(2):127-31. PubMed ID: 3915281
[TBL] [Abstract][Full Text] [Related]
10. Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer.
Martoni A; Pacciarini MA; Pannuti F
Eur J Cancer Clin Oncol; 1985 Jul; 21(7):803-6. PubMed ID: 3862582
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical evaluation of oral and intravenous 4-demethoxydaunorubicin.
Kavanagh JJ; Yeung KY; Savaraj N; Krakoff IH
Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1187-9. PubMed ID: 3865774
[TBL] [Abstract][Full Text] [Related]
12. Effect of 4-demethoxydaunorubicin (4-DMDR) in chronic myeloid leukemia in blastic transformation and relapsed acute leukemias.
Bandini G; Comotti B; Scapoli G; Leoni F; Di Prisco U; Mangoni L; Battista R; Tura S
Haematologica; 1985; 70(2):155-9. PubMed ID: 3924779
[No Abstract] [Full Text] [Related]
13. 4-Demethoxydaunorubicin administered orally in advanced breast cancer. A phase II study.
De Lena M; Brandi M; Bozzi D; Calabrese P; Romito S
Tumori; 1988 Feb; 74(1):65-70. PubMed ID: 3162625
[TBL] [Abstract][Full Text] [Related]
14. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin.
Smith DB; Margison JM; Lucas SB; Wilkinson PM; Howell A
Cancer Chemother Pharmacol; 1987; 19(2):138-42. PubMed ID: 3471367
[TBL] [Abstract][Full Text] [Related]
16. Disposition and metabolism of [14-14C] 4-demethoxydaunorubicin HCl (idarubicin) and [14-14C]daunorubicin HCl in the rat. A comparative study.
Zini G; Vicario GP; Lazzati M; Arcamone F
Cancer Chemother Pharmacol; 1986; 16(2):107-15. PubMed ID: 3456281
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of oral 4-demethoxydaunorubicin in previously treated (except anthracyclines) metastatic breast cancer patients.
Kolarić K; Mechl Z; Potrebica V; Sopkova B
Oncology; 1987; 44(2):82-6. PubMed ID: 3472133
[TBL] [Abstract][Full Text] [Related]
18. Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors.
Broggini M; Italia C; Colombo T; Marmonti L; Donelli MG
Cancer Treat Rep; 1984 May; 68(5):739-47. PubMed ID: 6586294
[TBL] [Abstract][Full Text] [Related]
19. High-performance liquid chromatographic method for pharmacokinetic studies on the new anthracycline 4-demethoxydaunorubicin and its 13-dihydro derivative.
Moro E; Bellotti V; Jannuzzo MG; Stegnjaich S; Valzelli G
J Chromatogr; 1983 May; 274():281-7. PubMed ID: 6575974
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]